Role of cyclosporine (CsA) in immuno-dermatological conditions

Rajagopalan, Murlidhar; Saraswat, Abir; Chandrashekar, ByalakereShivanna; Dhar, Sandipan; Dogra, Sunil; Tahiliani, Sushil; Raj, Praveen

doi:10.4103/idoj.idoj_189_22

Cited by 5 publications

(2 citation statements)

References 88 publications

(100 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A calcineurin inhibitor, targets T cells specifically, inhibiting the transcription of the interleukin 2 gene, modifying the immune response, and lowering inflammation in diseases such as atopic dermatitis, typically administered at a dose of "5 mg/kg/day" and available in multiple forms, including intravenous formulations, oral solutions, and gelatin capsules (Amber & Tabassum, 2020;Antti et al, 2021;Megna et al, 2017;Rajagopalan et al, 2022).…”

Section: Immunosuppressant's Cyclosporinementioning

confidence: 99%

Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids

Elsayed,

Khater

2024

Am. J. Life Sci. Innov.

View full text Add to dashboard Cite

Eczema, or atopic dermatitis, is a common, non-communicable, immune-mediated, inflammatory skin illness mainly affecting children. It is a chronic condition. It causes mental health problems like anxiety, sadness, anxiety, depression, hyperactivity, and obesity. It is the first skin ailment and the fifteenth non-fatal disease. The purpose of the present research study was to evaluate the Safety and Effectiveness of biological treatment for atopic dermatitis using monoclonal antibodies against non-biological treatment, including antibiotics, immunosuppressants, demards, histamine antagonists and corticosteroids. Patient information was gathered from FDA-approved clinical trials. The comparative analysis found that Biological therapies like Dupilumab, Omalizumab, and Ustekinumab improve symptoms and disease control in atopic dermatitis. Non-biological treatments may not be as effective. Early antibiotic exposure can increase infection vulnerability. Mild eczema infections require biological agents. Topical corticosteroids can be combined with Dupilumab for effective treatment of atopic dermatitis. Studies show that Dupilumab improves symptoms and quality of life, making it a better option than a placebo. FDA recommends using biological agents over immunosuppressants in paediatrics for improved immune results. FDA clinical trials showed that dupilumab is a safe and effective treatment for children with moderate-to-severe atopic dermatitis, reducing disease severity and improving quality of life in young AD patients.

show abstract

Section: Immunosuppressant's Cyclosporinementioning

confidence: 99%

Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids

Elsayed,

Khater

2024

Am. J. Life Sci. Innov.

View full text Add to dashboard Cite

show abstract

“…Cyclosporin A is used as an immunosuppressant drug [ 62 ]. Intradermal delivery of cyclosporin A has excellent potential to treat various skin diseases [ 63 , 64 ]. Boinpally et al investigated ItP-mediated delivery of lecithin liposomes encapsulating cyclosporin A across the epidermis of a human cadaver [ 65 ].…”

Section: Intradermal Delivery Of Various Macromolecules By Itpmentioning

confidence: 99%

Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis

Hasan,

Khatun,

Kogure

2023

Pharmaceutics

View full text Add to dashboard Cite

Messenger RNA (mRNA) vaccines against infectious diseases and for anticancer immunotherapy have garnered considerable attention. Currently, mRNA vaccines encapsulated in lipid nanoparticles are administrated via intramuscular injection using a needle. However, such administration is associated with pain, needle phobia, and lack of patient compliance. Furthermore, side effects such as fever and anaphylaxis associated with the lipid nanoparticle components are also serious problems. Therefore, noninvasive, painless administration of mRNA vaccines that do not contain other problematic components is highly desirable. Antigen-presenting cells reside in the epidermis and dermis, making the skin an attractive vaccination site. Iontophoresis (ItP) uses weak electric current applied to the skin surface and offers a noninvasive permeation technology that enables intradermal delivery of hydrophilic and ionic substances. ItP-mediated intradermal delivery of biological macromolecules has also been studied. Herein, we review the literature on the use of ItP technology for intradermal delivery of naked mRNA vaccines which is expected to overcome the challenges associated with mRNA vaccination. In addition to the physical mechanism, we discuss novel biological mechanisms of iontophoresis, particularly ItP-mediated opening of the skin barriers and the intracellular uptake pathway, and how the combined mechanisms can allow for effective intradermal delivery of mRNA vaccines.

show abstract

Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inﬂammation Inhibition in Mice

Far,

Saffari,

Jafari

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

Background Psoriasis is a chronic skin condition that is associated with persistent inflammation and skin lesions. Topical therapy has been a promising approach to the alleviation of psoriasis through the application of anti-inflammatory agents. Phosphatidylserine (PS) administration has shown anti-inflammatory effects in the trials. Consequently, the objective of this study was to evaluate the effects of topical PS on the potential improvement of an imiquimod (IMQ)-induced psoriasis model. Additionally, cyclosporine A was utilized as a comparative anti-psoriatic agent in our study. Methods The psoriasis model was established by topically applying IMQ to the dorsal skin of mice once daily for five consecutive days. The efficacy of topical PS was assessed using the Psoriasis Area and Severity Index (PASI) score to evaluate skin lesions. Subsequently, the skin samples were analyzed using Baker’s scoring system, Masson’s trichrome staining, immunohistochemistry, and real-time PCR analysis. Results IMQ-induced plaque-type psoriasis resulted in a significant increase (P<0.05) in dermal thickness, hyperkeratosis, PASI score, and inflammatory cytokines at the lesion site. The topical PS and cyclosporine A significantly (P<0.05) reduced PASI score and dermal thickness, while also alleviating erythema and scaling when compared to untreated mice. Furthermore, biomolecular assessments revealed that PS significantly (P<0.05) inhibited the gene expression of IL-17, IL-23, and TNF-α cytokines in the IMQ-induced lesions. Conclusion Topical PS may pointedly alleviate psoriasis through the inhibition of inflammation. The beneficial effects of the PS recommend further investigation in both experimental and clinical studies in the control of skin psoriasis.

show abstract

Role of cyclosporine (CsA) in immuno-dermatological conditions

Cited by 5 publications

References 88 publications

Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids

Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids

Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis

Phosphatidylserine Topically Attenuates Imiquimod-induced Psoriasis Through Inﬂammation Inhibition in Mice

Contact Info

Product

Resources

About